The authors tested the efficacy of the synZiFTR platform in regulating the multifunctional output of CAR T cells in vivo using a xenograft liquid tumor model, and the results also demonstrated that an independent and sufficient supply of IL-2 is crucial for driving synergistic therapeutic responses in cooperation with CAR activation [4]. This evidence concerns the gene IL2 and neoplasm.